Pannexin 1 – a novel target for pediatric orphan epilepsy
Epilepsy is a group of syndromes with high unmet medical need, especially in children as frequent seizures affect the immature brain and its development. In some orphan syndromes, drug resistance is 70% with dramatic consequences...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PanThera
Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Mo...
150K€
Cerrado
oils4cure
Oils4cure: finding an effective drug to alleviate Refractory...
2M€
Cerrado
RTI2018-098768-B-I00
PATOFISIOLOGIA DE LOS COMPLEJOS NMADR-BK EN EL CEREBRO
230K€
Cerrado
RTI2018-095784-B-I00
DESARROLLO DE NUEVAS TERAPIAS EN LAS EPILEPSIAS GENETICAS ME...
172K€
Cerrado
WWOXAID
A Promising Treatment of WWOX Associated Neurological Disord...
150K€
Cerrado
EpiPrevent
The P2X7 receptor as treatment target for traumatic brain in...
216K€
Cerrado
Información proyecto PANNEXIN
Duración del proyecto: 24 meses
Fecha Inicio: 2023-09-26
Fecha Fin: 2025-09-30
Líder del proyecto
PANNTHERAPI
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Descripción del proyecto
Epilepsy is a group of syndromes with high unmet medical need, especially in children as frequent seizures affect the immature brain and its development. In some orphan syndromes, drug resistance is 70% with dramatic consequences for patients and their families. Novel treatments must prevent the negative effects of seizures, but also minimize off-target effects on brain development and cognitive functions. Our solution is the specific blockade of the activated form of the Pannexin 1 (Panx1) channel using a reformulated form of probenecid: PTI5803. This compound, a first-in-class drug, inhibits seizures preclinically in >80% of cases without hampering cognitive functions. Designed to be adapted to children (from 6 months of age) and to improve the bioavailability, PTI5803 is a highly specific breakthrough product to counteract the pathological activation of Panx1 in patients with an ultra-resistant orphan epilepsy, with the potential to disrupt the market of paediatric epilepsy.